Adults 18 to 99, any sex, with Kidney Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
3D CEUS Generated Metrics in Kidney Mass: Wash_In_SlopePrimary· Baseline- up to 3 minutes
A study-specific model was created to predict kidney tumor type. The contrast-enhanced ultrasonogram (CEUS) Wash\_In\_Slope parameter was generated. This metric indicates the change in contrast with time in the mass using bolus imaging. Bolus imaging injects a small amount of contrast agent and monitors the contrast agent as it flows in (wash-in) and out (wash-out) of the body/mass. The intensity of the signal (the brightness of the image) is plotted over time to generate the time-intensity curve. The intensity of the signal (the brightness of the image) values range between 0=black, and 255=W
Group
Value
95% CI
CEUS Imaging Parameters
7.60
3.13 – 12.28
3D CEUS Generated Metric in Kidney Mass: Wash_In_interceptPrimary· Baseline- up to 3 minutes
A study-specific model was created to predict kidney tumor type. The contrast-enhanced ultrasonogram (CEUS) Wash\_In\_intercept parameter was generated. This metric indicates the intensity level prior to infusion of contrast. The intensity of the signal (the brightness of the image) values range between 0=black, and 255=white. This value was calculated using an equation for a line which has a slope and the intercept. The values were negative because they were calculated (not measured).
Group
Value
95% CI
CEUS Imaging Parameters
-18.30
-149.6 – 62.11
3D CEUS Generated Metric in Kidney Mass: Wash_Out_SlopePrimary· Baseline- up to 3 minutes
A study-specific model was created to predict kidney tumor type. The contrast-enhanced ultrasonogram (CEUS) Wash\_Out\_Slope parameter was generated. This metric indicates the change in contrast with time in the mass using bolus imaging. Bolus imaging injects a small amount of contrast agent and monitors the contrast agent as it flows in (wash-in) and out (wash-out) of the body/mass. The intensity of the signal (the brightness of the image) is plotted over time to generate the time-intensity curve. The intensity of the signal (the brightness of the image) value range was between 0=black and 25
Group
Value
95% CI
CEUS Imaging Parameters
-0.93
-2.09 – -0.41
3D CEUS Generated Metric in Kidney Mass: Wash_Out_InterceptPrimary· Baseline- up to 3 minutes
A study-specific model was created to predict kidney tumor type. The contrast-enhanced ultrasonogram (CEUS) Wash\_Out\_Intercept parameter was generated. This metric indicates the intensity level of contrast at a steady state of enhancement in the mass. The intensity of the signal (the brightness of the image) values range between 0=black, and 255=White. This value was calculated using an equation for a line that has a slope and an intercept.
Group
Value
95% CI
CEUS Imaging Parameters
125.84
43.28 – 199.71
3D CEUS Generated Metric in Kidney Mass: FR_aPrimary· Baseline- up to 3 minutes
A study-specific model was created to predict kidney tumor type. The contrast-enhanced ultrasonogram (CEUS) FR\_a parameter was generated. The intensity of the signal (the brightness of the image) value range is between 0=black, and 255=white. The intensity was plotted by time. FR\_a parameters were devised from an exponential fit. The exponential fit of the data provides the height of the curve.
Group
Value
95% CI
CEUS Imaging Parameters
102.84
61.01 – 152.8
3D CEUS Generated Metric in Kidney Mass: FR_betaPrimary· Baseline- up to 3 minutes
A study-specific model was created to predict kidney tumor type. The contrast-enhanced ultrasonogram (CEUS) FR\_beta parameter was generated. The intensity of the signal (the brightness of the image) value range is between 0=black, 255=White. The intensity was plotted by time. FR\_beta parameters were devised from an exponential fit. Exponential fit of the data provides the slope of the curve.
Group
Value
95% CI
CEUS Imaging Parameters
0.16
0.03 – 0.77
3D CEUS Generated Metric in Kidney Mass: VolumePrimary· Baseline- up to 3 minutes
A study-specific model was created to predict kidney tumor type. The contrast-enhanced ultrasonogram (CEUS) volume parameter was generated. The volumes were generated using the ellipsoid equation on the CEUS image of the kidney mass.
Group
Value
95% CI
CEUS Imaging Parameters
60.80
3.08 – 271.97
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. Wash_In_SlopePrimary· Baseline- up to 3 minutes
The association between tumor pathology type (Clear cell renal carcinoma (CCRCC) versus none (CCRCC) pathology) and CEUS-generated Wash\_In\_Slope parameter was studied. This metric indicates the change in contrast intensity with time in the mass using bolus imaging. The intensity of the signal (the brightness of the image) values range between 0=black, and 255=White. The Wash\_In\_Slope increases as the contrast agent is introduced to the body/mass. This value was generated by fitting the data to a linear equation. Increasing brightness is related to the slope of the curve.
Group
Value
95% CI
Clear Cell Renal Carcinoma
7.61
± 2.33
Papillary Carcinoma
3.13
± NA
Clear Cell Papillary
4.23
± NA
Chromophobe
10.56
± NA
Other
12.28
± NA
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. Wash_In_interceptPrimary· Baseline- up to 3 minutes
The association between tumor pathology type (Clear cell renal carcinoma (CCRCC) versus none (CCRCC) pathology) and CEUS-generated Wash\_In\_intercept parameter was studied. This metric indicates the intensity level prior to infusion of contrast. The intensity of the signal (the brightness of the image) value range is between 0=black, and 255=White. This value was calculated using an equation for a line which has a slope and the intercept. The values were negative because they were calculated (not measured).
Group
Value
95% CI
Clear Cell Renal Carcinoma
-11.02
± 58.96
Papillary Carcinoma
-1.07
± NA
Clear Cell Papillary
31.12
± NA
Chromophobe
-53.10
± NA
Other
-122.88
± NA
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. Wash_Out_SlopePrimary· Baseline- up to 3 minutes
The association between tumor pathology type (Clear cell renal carcinoma (CCRCC) versus none (CCRCC) pathology) and CEUS-generated Wash\_Out\_Slope parameter was studied. This metric indicates the change in contrast intensity with time in the mass using bolus imaging. The intensity of the signal (the brightness of the image) value range is between 0=black, and 255=White. Decreasing brightness is related to the slope of the curve. The Wash Out slope decreases as the contrast agent clears the body/mass. Decreasing brightness is related to the slope of the curve. This results in a negative number
Group
Value
95% CI
Clear Cell Renal Carcinoma
7.62
± 2.33
Papillary Carcinoma
3.13
± NA
Clear Cell Papillary
4.23
± NA
Chromophobe
10.56
± NA
Other
12.3
± NA
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. Wash_Out_InterceptPrimary· Baseline- up to 3 minutes
The association between tumor pathology type (Clear cell renal carcinoma (CCRCC) versus none (CCRCC) pathology) and CEUS-generated Wash\_Out\_Intercept parameter was studied. This metric indicates the intensity level of contrast at steady state of enhancement in the mass. The contrast-enhanced ultrasonogram (CEUS) Wash\_Out\_Intercept parameter was generated. The intensity of the signal (the brightness of the image) value range is between 0=black, and 255=White. This value was calculated using an equation for a line which has a slope and the intercept.
Group
Value
95% CI
Clear Cell Renal Carcinoma
137.95
± 36.88
Papillary Carcinoma
-0.43
± NA
Clear Cell Papillary
118.53
± NA
Chromophobe
139.01
± NA
Other
148.49
± NA
3D CEUS Generated Metric in Kidney Mass - Histopathologic Type vs. FR_aPrimary· Baseline- up to 3 minutes
The association between tumor pathology type (Clear cell renal carcinoma (CCRCC) versus none (CCRCC) pathology) and CEUS-generated FR\_a parameter was studied. The intensity of the signal (the brightness of the image) values range between 0=black, and 255=White. The intensity was plotted by time. FR\_a parameters were devised from an exponential fit. The exponential fit of the data provides the height of the curve.
Group
Value
95% CI
Clear Cell Renal Carcinoma
105.34
± 27.09
Papillary Carcinoma
0
± NA
Clear Cell Papillary
0
± NA
Chromophobe
0
± NA
Other
0
± NA
Sponsor's own description
The purpose of this study is to determine if contrast-enhanced ultrasound can detect abnormal features of kidney lesions in patients with suspected kidney cancer with the same accuracy as conventional ultrasound and contrast-enhanced magnetic resonance imaging (MRI)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
· Phase 1, PHASE2
· recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
· Phase 2
· recruiting
NCT06964958 — 177LuPSMA in Renal Cell Carcinoma
· Phase 2
· active not recruiting
Other UNC Lineberger Comprehensive Cancer Center trials
Trials by the same sponsor.
NCT06656936 — The PharmFIT Study
· NA
· not yet recruiting
NCT05937659 — Incorporating Biometric Data for Patients Receiving Concurrent Chemotherapy & RT
· not yet recruiting
NCT07479199 — Local Radiofrequency Ablation Plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors
· not yet recruiting
NCT07069595 — PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
· Phase 2
· recruiting
NCT04266730 — Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
· Phase 1
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UNC Lineberger Comprehensive Cancer Center
Last refreshed: 13 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04021238.